1. Home
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Packaging, Application, End User, and Distribution Channel

Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Packaging, Application, End User, and Distribution Channel

  • October 2022
  • 216 pages
  • ID: 6353526
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

The Middle East low molecular weight heparin market is expected to grow from US$ 151.15 million in 2021 to US$ 209.60 by 2028. It is estimated to grow at a CAGR of 4.8% from 2022 to 2028. The report highlights prevailing trends and factors driving the market growth.
The growth of the Middle East low molecular weight heparin market is attributed to the advantage of low molecular weight heparin anticoagulant over unfractionated heparin . However, the adverse effect of low molecular weight heparin is hindering the overall market growth.
Low molecular weight heparin (LMWH) is a class of anticoagulants.They are used to prevent blood clots and treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and treat myocardial infarction.

LMWHs are defined as heparin salts with an average molecular weight of less than 8,000 Daltons and in which at least 60% of all chains have a molecular weight of less than 8,000 Da.These are obtained by various methods of fractionation or depolymerization of polymeric heparin.

Low molecular weight heparin offers advantages over heparin such that it has better bioavailability and longer half-life, simplified dosing, predictable anticoagulant response, and lower risk of osteoporosis.
Advantages of Low Molecular Weight Heparin Anticoagulants over Unfractionated Heparin
The effects of unfractionated heparin (UFH) or standard heparin vary from patient to patient.Therefore, it can only be administered to hospitalized patients under supervision.

However, low molecular weight heparins (LMWH) can be subcutaneously administered daily without supervision.In addition, LMWH has predictable pharmacokinetic properties to unfractionated heparin, which allows its administration in fixed doses based on laboratory monitoring without needing dose adjustments.

The low molecular weight fractions of heparin have a molecular weight of ~3,500–8,000 Daltons , while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former reacts less with platelets than the latter.
Moreover, LMWH is less likely to induce immune allergic thrombocytopenia, which is a severe side effect caused by unfractionated heparin (UFH).This side effect is often complicated for patients suffering from arterial thrombosis.

In addition, properties such as better bioavailability, predictable dose-response, and longer plasma half-life than unfractionated heparin make LMWH a preferred choice for anticoagulation therapy.
LMWH anticoagulants prevent the clotting of blood and the growth of existing blood clots in blood vessels.In recent years, the development of prevention methods and pharmacological and surgical treatment of thrombosis have improved considerably.

LMWHs have been used in the treatment of antithrombotic diseases for the past two decades.LMWH exhibits anticoagulant properties such as antitumor, anti-inflammatory, and antiproliferative effects, which are useful in the treatment of pathologies such as nephrotic syndrome and Alzheimer’s disease.

Thus, the advantages of LMWH anticoagulants over unfractionated heparin are driving the Middle East low molecular weight heparin market.
Based on product, the Middle East low molecular weight heparin market is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others.The enoxaparin segment held the largest market share in 2021.

The dalteparin segment is anticipated to register the highest CAGR in the market during the forecast period.
In terms of packaging, the market is bifurcated into multi-vials and pre-filled syringes.The multi-vials segment held a larger share in 2021.

The prefilled syringes segment is anticipated to register a higher CAGR during the forecast period.
Based on application, the Middle East low molecular weight heparin market is segmented into deep vein thrombosis, acute coronary syndrome, pulmonary embolism, and others.The deep vein thrombosis segment led the market in 2021.

However, the acute coronary syndrome segment is expected to grow at the highest CAGR during the forecast period.
In terms of end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others.The hospitals segment accounted for a maximum share in 2021.

However, the clinics segment is expected to grow at the highest CAGR during the forecast period.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the maximum share in 2021, and the retail pharmacies segment is expected to grow at the highest CAGR during the forecast period.
Impact of COVID-19 Pandemic on Middle East Low molecular weight heparin Market
In the past several decades, countries in the Middle East have strengthened their health systems, along with upgrading public and commercial healthcare.However, the limited availability of resources (including trained staff and medical equipment) and the burden of noncommunicable diseases harm the overall healthcare system in the region.

In 2020, the COVID-19 pandemic had a significant impact on the delivery and accessibility of social services, education, health and nutrition, healthcare spending, and well-being.Owing to the dependence of the region on trade and tourism, and struggles with substantial youth unemployment, the global crisis led to serious long-term effects on the region.

Governments in the Middle East allocated funds to prevent the overburdening of their health systems and decelerate the spread of COVID-19 in 2020; a few countries also emphasized on increasing the number of intensive care units and hospital beds.
According to the National Institute of Health (NIH) report (2020), low molecular weight heparin utilization was high during the COVID-19 pandemic.In COVID-19-induced acute respiratory distress syndrome, the lungs could not fill with sufficient air, causing hypoxemia and high mortality among hospitalized patients.

Therefore, patients with evidently worst clinical presentation were prescribed low molecular weight heparin via a soft mist inhaler dosing 4000 IU per administration twice daily.
Various organic and inorganic strategies are adopted by companies operating in the Middle East low molecular weight heparin market.The organic strategies mainly include product launches and product approvals.

Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships.These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth.

Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few significant developments by key players in the Middle East low molecular weight heparin market are listed below.
• In April 2022, Hikma Pharmaceuticals PLC announced the acquisition of Custopharm Hikma, which is the second-largest supplier of generic sterile injectable medicines used by hospitals and health care providers in the US. The combination with Custopharm will enhance Hikma’s R&D capabilities and pipeline and expand Hikma’s differentiated US portfolio to close to 130 commercialized injectable medicines—a more than fivefold increase over the last decade.
• In May 2019, the US Food and Drug Administration (FDA) approved the use of Pfizer’s anticoagulant medicine Fragmin (Dalteparin sodium) to minimize the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients aged one month and above.
• In June 2018, Laboratorios Farmaceúticos Rovi S.A. signed a licensing agreement with Sandoz, a division of Novartis AG and one of the global leaders in generic pharmaceuticals and biosimilars, to distribute and market its Enoxaparin biosimilar.
The American Medical Association, the British Journal of Surgery, and the National Library of Medicine are among the major primary and secondary sources referred to while preparing the report on the Middle East low molecular weight heparin market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Asia-Pacific Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product, Disease Indication, Procedure, and End User

  • $ 3000
  • November 2022
  • 192 pages

The embolotherapy market in Asia Pacific is expected to grow from US$ 781.80 million in 2022 to US$ 1,272.58 million by 2028. It is estimated to grow at a CAGR of 8.5% from 2022 to 2028. Growing Use of ...

  • APAC
  • Cancer
  • Cardiovascular Disease
  • Industry analysis
  • Chronic Disease Prevalence
  • Health Expenditure


Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on